Search results for "Placement."

showing 10 items of 1123 documents

Effect of undersized drilling on the stability of immediate tapered implants in the anterior maxillary sector. A randomized clinical trial.

2020

Background To evaluate the effect of undersized drilling on the primary and secondary stability of immediate implants placed in the anterior maxilla. Material and Methods A comparative randomized clinical trial was carried out in 30 healthy adults. Thirty tapered implants, 16 involving conventional drilling and 14 undersized drilling, were placed immediately after anterior maxillary tooth removal. Insertion torque and implant stability assessed by resonance frequency analysis (RFA) were evaluated at three different timepoints: at implant placement and 6 and 12 weeks post-implantation. The results were compared using parametric statistical tests. Results All implants showed adequate stabilit…

AdultDentistryOsseointegrationMaxillary toothlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawBone DensityOsseointegrationosteoradionecrosisMaxillaMedicineHumansradiotherapy bone necrosisGeneral DentistryUNESCO:CIENCIAS MÉDICASteriparatideDental Implantsbusiness.industryResearchDental Implantation EndosseousResonance Frequency AnalysisDrilling030206 dentistrylow level laser therapyImplant placementResonance frequency analysispentoxifyllineOtorhinolaryngologyTorquehyperbaric oxygenMaxillaSurgeryImplantbusinessImplantologyMedicina oral, patologia oral y cirugia bucal
researchProduct

AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement.

2020

Lysosomal storage diseases (LSDs) are a heterogeneous group of inherited disorders caused by loss-of-function mutations in genes encoding for lysosomal enzymes/proteins. The consequence is a progressive accumulation of substrates in these intracellular organelles, resulting in cellular and tissue damage. The overall incidence is about 1/8000 live births, but is likely underestimated. LSDs are chronic progressive multi-systemic disorders, generally presenting with visceromegaly, and involvement of the central nervous system, eyes, the skeleton, and the respiratory and cardiovascular systems. The age at onset and phenotypic expression are highly variable, according to the specific enzymatic d…

AdultHepatosplenomegalyLysosomal acid lipase deficiencyBioinformaticsOrganomegaly03 medical and health sciencesLiver disease0302 clinical medicinemedicineCholesteryl ester storage disease Enzyme replacement therapy Gaucher disease Lysosomal acid lipase Niemann–Pick disease deficiency Substrate reduction therapyHumansSubstrate reduction therapyEnzyme Replacement TherapySocieties MedicalNiemann-Pick DiseasesAcid sphingomyelinase deficiencyGaucher DiseaseHepatologybusiness.industryGastroenterologyWolman DiseaseEnzyme replacement therapymedicine.diseaseLysosomal Storage DiseasesSphingomyelin PhosphodiesteraseItaly030220 oncology & carcinogenesis030211 gastroenterology & hepatologymedicine.symptombusinessNiemann–Pick diseaseLysosomesVisceromegalyDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Physiological Estrogen Replacement May Enhance the Effectiveness of the Gonadotropin-Releasing Hormone Agonist in the Treatment of Hirsutism

1994

GnRH agonists (GnRH-A) have been used for the treatment of hirsutism in women with ovarian hyperandrogenism. However, significant side-effects, including vasomotor symptoms and bone loss, have prevented the long term use of this therapy. In this study, we evaluated the effects of low dose (physiological) estrogen replacement on the side-effects and clinical and hormonal parameters of 22 hirsute women with ovarian hyperandrogenism when treated with a long-acting GnRH-A, Decapeptyl. Ten patients with Ferriman-Gallwey (FG) scores averaging 13.4 +/- 1.5 were randomly assigned to be treated with Decapeptyl alone (3.75 mg, im, every 28 days for 6 months), and 12 other patients with FG scores aver…

AdultHirsutismendocrine systemmedicine.medical_specialtyAdolescentmedicine.drug_classEndocrinology Diabetes and MetabolismClinical BiochemistryOvaryMedroxyprogesterone AcetateGonadotropin-releasing hormoneBiochemistryGonadotropin-Releasing HormoneEndocrinologyGonadotropin-releasing hormone agonistInternal medicinemedicineHumansMedroxyprogesterone acetateEstrogen replacementConjugated Equine EstrogensTestosteronehirsutismTriptorelin PamoateVasomotorbusiness.industryEstrogen Replacement TherapyBiochemistry (medical)HyperandrogenismObstetrics and GynecologyDrug SynergismGeneral Medicinemedicine.diseaseMenstruationmedicine.anatomical_structureEndocrinologyEstrogenGonadotropins PituitaryAndrogensDrug Therapy CombinationFemalebusinesshormones hormone substitutes and hormone antagonistsHormonemedicine.drugObstetrical & Gynecological Survey
researchProduct

Neuromuscular function and mechanical efficiency of human leg extensor muscles during jumping exercises

1982

The influence of prestretch amplitude on the mechanical efficiency was examined with 5 subjects, who performed 5 different series of vertical jumps, each of which differed with respect to the mechanics of the knee joint action during the prestretch (eccentric) phase of the contact on the floor. Electromyographic activity was recorded from the major extensor muscles during the entire work period of 1 min per series. In addition, expired air was collected during the test and recovery for determination of energy expenditure. Mechanical work was calculated from the vertical displacement of the body during the jumps. The results indicated that high net efficiency of 38.7% was observed in conditi…

AdultLegMaterials sciencemedicine.diagnostic_testElectromyographyPhysiologyMusclesPhysical ExertionWork (physics)Neuromuscular JunctionAnatomyElectromyographyConcentricmedicine.disease_causeElasticityStretch shortening cycleOxygen ConsumptionJumpingmedicineHumansEccentricHuman legVertical displacementBiomedical engineeringActa Physiologica Scandinavica
researchProduct

Gastrointestinal disturbances and their management in miglustat‐treated patients

2011

Miglustat (Zavesca®) is approved for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease (GD1) for whom enzyme replacement therapy is unsuitable, and for the treatment of progressive neurological manifestations in adult and paediatric patients with Niemann-Pick disease type C (NP-C). Gastrointestinal disturbances such as diarrhoea, flatulence and abdominal pain/discomfort have consistently been reported as the most frequent adverse events associated with miglustat during clinical trials and in real-world clinical practice settings. These adverse events are generally mild or moderate in severity, occurring mostly during the initial weeks of therapy. The mechanis…

AdultLoperamideAbdominal painmedicine.medical_specialty1-DeoxynojirimycinMalabsorptionDrug-Related Side Effects and Adverse ReactionsGastrointestinal DiseasesModels BiologicalGastroenterologyInternal medicineMiglustatGeneticsmedicineHumansEnzyme InhibitorsChildAdverse effectGenetics (clinical)Clinical Trials as TopicGaucher Diseasebusiness.industryEnzyme replacement therapymedicine.diseaseClinical trialEndocrinologymedicine.symptombusinessFlatulencemedicine.drugJournal of Inherited Metabolic Disease
researchProduct

Cholelithiasis in Patients with Gaucher Disease type 1: Risk Factors and the Role of ABCG5/ABCG8 Gene Variants

2016

Background & Aim: Patients with Gaucher disease type 1 (GD1) show an altered lipid profile and a certain degree of insulin resistance, which might contribute to cholelithiasis (CL) and could possibly be associated with ABCG5/ABCG8 gene variants. We aimed to investigate the prevalence of CL in Caucasian adult patients with GD1 and the possible risk factors, including gene variants of the ABCG5/ABCG8 genes.
 Methods: 61 Caucasian patients with GD1 (38 female/23male), aged 18-62 years and 61 healthy subjects matched for age, gender and BMI, without CL, for comparison of lipid profiles. Data before start of enzyme replacement therapy (ERT) were recorded: clinical, haematological, sever…

AdultMale0301 basic medicineHeterozygotemedicine.medical_specialtyAdolescentLipoproteinsmedicine.medical_treatmentSplenectomyABCG8030105 genetics & heredityGastroenterologyWhite PeopleYoung Adult03 medical and health sciencesInsulin resistanceGene FrequencyCholelithiasisRisk FactorsInternal medicineGenotypePrevalencemedicineHumansEnzyme Replacement TherapyGenetic Predisposition to DiseaseATP Binding Cassette Transporter Subfamily G Member 5Genetic Association StudiesGaucher Diseasemedicine.diagnostic_testRomaniabusiness.industryATP Binding Cassette Transporter Subfamily G Member 8HomozygoteGastroenterologyCase-control studyGenetic VariationEnzyme replacement therapyMiddle Agedmedicine.diseaseCross-Sectional StudiesPhenotypeCase-Control StudiesGlucosylceramidaseFemaleLipid profilebusinessDyslipidemiaJournal of Gastrointestinal and Liver Diseases
researchProduct

Growth hormone replacement in adults:Real-world data from two large studies in US and Europe

2020

Objective: This report describes the effectiveness and safety of growth hormone replacement in 3180 adult patients with growth hormone deficiency followed-up for 0.0–12.2 years in two completed, complementary, non-interventional, multicentre studies, NordiNet® International Outcome Study (IOS) (NCT00960128) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program (NCT01009905). Design: In both studies, Norditropin® (somatropin; Novo Nordisk A/S, Denmark) was administered at the discretion of the treating physician and according to routine practice. We present data on baseline characteristics, growth hormone dose, safety data and change from baseline in waist circumferenc…

AdultMale0301 basic medicineIGF-I SDSPediatricsmedicine.medical_specialtyWaistHormone Replacement TherapyEndocrinology Diabetes and MetabolismANSWER Program030209 endocrinology & metabolismEffectivenessGrowth hormoneNordiNet® International Outcome Study (IOS)Body compositionHypopituitarismBody Mass IndexGrowth hormone deficiency03 medical and health sciences0302 clinical medicineEndocrinologyElectric ImpedancemedicineHumansGrowth hormone replacementAgedAdult patientsHuman Growth Hormonebusiness.industryMiddle Agedmedicine.diseaseRecombinant ProteinsUnited StatesReal-world dataEuropeClinical Practice030104 developmental biologyGrowth hormone deficiency in adultsBaseline characteristicsBody CompositionFemaleWaist CircumferenceSafetybusinessReal world dataBody mass index
researchProduct

Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before an…

2020

Rossella Parini,1,2 Guillem Pintos-Morell,3 Julia B Hennermann,4 Ting-Rong Hsu,5 Nesrin Karabul,6 Vasiliki Kalampoki,7 Andrey Gurevich,7 Uma Ramaswami8 On behalf of the FOS Study Group1Rare Metabolic Diseases Unit, MBBM Foundation, San Gerardo Hospital, Reference Centre for Hereditary Metabolic Disorders (MetabERN), Monza, Italy; 2TIGET Institute, IRCCS San Raffaele Hospital, Milan, Italy; 3Division of Rare Diseases, Reference Centre for Hereditary Metabolic Disorders (MetabERN), University Hospital Vall d’Hebron, Autonomous University of Barcelona, Barcelona, Spain; 4Villa Metabolica, Department of Pediatric and Adolescent Medicine, University Medical Center, Mainz, Germany; 5Dep…

AdultMale0301 basic medicinemedicine.medical_specialtyestimated glomerular filtration rateAdolescentPharmaceutical ScienceRenal functionLeft ventricular hypertrophyFabry Outcome SurveyYoung Adult03 medical and health sciences0302 clinical medicineInternal medicineDrug DiscoverymedicineHumansEnzyme Replacement TherapyEstimated glomerular filtration rateChildAgalsidase alfaOriginal ResearchRetrospective StudiesPharmacologyagalsidase alfaFabry diseaseProteinuriaDrug Design Development and Therapybusiness.industryLeft ventricular hypertrophyEnzyme replacement therapyMiddle Agedmedicine.diseaseFabry diseaseRecombinant Proteinsleft ventricular hypertrophyIsoenzymesTreatment Outcome030104 developmental biologyMale patientalpha-Galactosidase030220 oncology & carcinogenesisEnzyme replacement therapyCohortmedicine.symptombusinessAgalsidase alfa
researchProduct

Does the coordination between posture and movement during human whole-body reaching ensure center of mass stabilization?

1999

The whole-body center of mass (CoM) has been classically regarded as the stabilized reference value for human voluntary movements executed upon a fixed base of support. Axial synergies (opposing displacements of head and trunk with hip segments) are believed to minimize antero-posterior (A/P) CoM displacements during forward trunk movements. It is also widely accepted that anticipatory postural adjustments (APAs) create forces of inertia that counteract disturbances arising from the moving segment(s). In the present study, we investigated CoM stabilization by axial synergies and APAs during a whole-body reaching task. Subjects reached towards an object placed on the ground in front of them …

AdultMaleAdolescentComputer sciencemedia_common.quotation_subjectMovementeducationPostureKinematicsInertiaControl theorymedicineHumansDisplacement (orthopedic surgery)media_commonMovement (music)ElectromyographyGeneral NeuroscienceMotor controlBody movementTrunkSagittal planemedicine.anatomical_structureArmFemalePsychomotor PerformanceExperimental brain research
researchProduct

Consensus Document on substitution therapy with DHEA in the elderly

2006

AdultMaleAgingmedicine.medical_specialtyHormone Replacement TherapyAlternative medicineSocio-culturaleAdult; Aged; Aged 80 and over; Aging; Atherosclerosis; Bone Diseases Metabolic; Cognition Disorders; Dehydroepiandrosterone; Female; Hormone Replacement Therapy; Humans; Italy; Male; Middle Aged80 and overAdrenal insufficiencyHumansMedicineSubstitution therapyIntensive care medicineAgedAged 80 and overbusiness.industryGeriatrics gerontologyDehydroepiandrosteroneMiddle AgedAtherosclerosismedicine.diseaseConsensus Document elderly adrenal insufficiency adrenopause DHEA DHEAS DHEA substitution therapyBone Diseases MetabolicItalyPhysical therapyFemaleMetabolicBone DiseasesGeriatrics and GerontologyCognition DisordersbusinessAging Clinical and Experimental Research
researchProduct